Analysts are intrested in these 5 stocks: ( (HAS) ), ( (RITM) ), ( (BA) ), ( (VLO) ) and ( (CLDX) ). Here is a breakdown of their recent ratings and the rationale behind them.
Hasbro is catching the attention of investors with a recent upgrade from analyst James Hardiman, who moved the stock from Neutral to Buy. The driving force behind this upgrade is the impressive performance of Wizards of the Coast (WotC), which has seen a significant increase in guidance. Despite tariff challenges, Hasbro’s management has maintained its full-year guidance, showcasing confidence in its strategic direction. The company’s first-quarter results exceeded expectations, with a notable increase in revenue and adjusted EBITDA. The positive outlook for Hasbro is further supported by cost-saving measures and an optimistic view of future tariff impacts.
Rithm Capital has been upgraded to Overweight by analyst Crispin Love, who sees the company’s diversified model as a strong asset. The stock is trading at a discount, which presents an attractive opportunity for investors. Rithm’s recent performance has been solid, with a notable core return on equity and a robust servicing portfolio that can thrive even in elevated rate environments. The company’s ambitions in asset management, bolstered by the Sculptor acquisition, add to its growth potential. With an increased price target, Rithm is positioned for a promising future.
Boeing has been upgraded to Outperform by analyst Douglas Harned, with a new price target reflecting a more optimistic outlook. The company is making strides in its production capabilities, particularly with the 737MAX and 787 models. Boeing’s defense business is also gaining momentum, thanks to recent contract wins. While challenges remain, such as tariff impacts and certification risks, the overall trajectory for Boeing is positive. The company’s financial health is supported by strategic moves like the sale of Jeppesen, which enhances liquidity.
Valero Energy has seen a shift in analyst sentiment, with Neil Mehta upgrading the stock to Neutral. The change comes as consensus revisions better align with the current refining landscape, and the crude environment shows signs of improvement. Valero’s balance sheet remains strong, supporting its commitment to shareholder returns. While the demand environment is uncertain, the supply side appears more favorable, offering potential margin support. The company’s strategic positioning and financial health make it a stock to watch.
Celldex is making waves in the biotech sector with a Buy rating from analyst Edward Nash. The company’s lead drug candidate, barzolvolimab, is showing promise across multiple indications in the Immunology & Inflammation space. With ongoing Phase III trials and a strong pipeline, Celldex is poised for significant growth. The company’s innovative approach, experienced management team, and solid financial position further bolster its prospects. As the competitive landscape evolves, Celldex is well-positioned to capitalize on emerging opportunities.